<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299425</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 192486</org_study_id>
    <secondary_id>5R01CA212147-02</secondary_id>
    <nct_id>NCT04299425</nct_id>
  </id_info>
  <brief_title>Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy</brief_title>
  <acronym>NIRAF</acronym>
  <official_title>Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study describes a single center, randomized, single-blinded clinical trial to assess the
      clinical benefits of the use of near infrared autofluorescence (NIRAF) detection with an
      FDA-cleared device 'Parathyroid Eye (PTeye)' for identifying parathyroid glands (PGs) during
      parathyroidectomy (PTx) procedures. It compares risk-benefits and outcomes in PTx patients
      where NIRAF detection with PTeye for parathyroid identification is either used or not used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inability of the surgeon to identify or localize the diseased PG can occur in 5 - 10% of
      cases resulting in failed parathyroidectomies (PTx). As a result, persistent
      hyperparathyroidism can occur in these patients resulting in unnecessary repeat surgeries
      that may be associated with increased morbidity and costs. Ultrasound imaging,
      99mTechnetium-sestamibi scintigraphy, and computed tomography (CT) have so far demonstrated
      variable efficacy in preoperative localization of diseased PGs and may not always correlate
      well with the surgical field of view as observed intraoperatively. Consequently, most
      surgeons rely on visual identification of PGs during surgery, whereby the accuracy of PG
      identification is eventually determined by her/his surgical skill and experience. When in
      doubt, a surgeon routinely confirms the identity of PG tissue intraoperatively by sending the
      specimen for frozen section analysis that typically requires a wait time of 20-30 minutes per
      sample and has additional costs.

      By easily being able to distinguish parathyroid from other tissues intraoperatively,
      postsurgical complications and associated costs may be reduced. The unique discovery of near
      infrared autofluorescence (NIRAF) in parathyroid tissues demonstrated that optical modalities
      that detect NIRAF can be utilized for non-invasive and label-free identification of
      parathyroid tissues with an accuracy as high as 97%. Since then, several research groups have
      explored the feasibility of localizing parathyroid glands using NIRAF detection with
      reasonable success, resulting in FDA clearance for marketing this optical technique. In this
      study, we plan to evaluate whether an FDA-cleared device called 'PTeye' (AiBiomed, Santa
      Barbara, CA) is beneficial or not, for the surgeon and patient during PTx operations. The
      results of such a study will help us to understand and assess the true impact of optical
      modalities such as PTeye on (i) improving the quality and efficiency of PTx surgeries and
      (ii) minimizing risk of postsurgical complications and related expenses.

      The aim of this prospective single blinded randomized study is to compare 2 groups of
      patients: PTx patients operated using NIRAF detection technology with PTeye as adjunct tool
      (NIRAF+) vs. patients operated without the adjunct technology (NIRAF-). The main objective of
      this study is to assess the benefit of intraoperative use of NIRAF detection technology via
      PTeye during PTx procedures with regard to PG identification, duration of surgery, number of
      frozen section analysis performed, number of intraoperative PTH assays sent and incidence of
      postsurgical complications, if any and history of ER visits or hospitalization or repeat
      surgeries due to persistent high blood calcium after PTx procedure, compared to standard of
      care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>NIRAF detection technology is used as an adjunctive tool for intraoperative parathyroid identification in patients who undergo parathyroidectomy (PTx) in the interventional group.
Generic Name of Device: Parathyroid Autofluorescence Detection Device (NIRAF detection technology).
The Parathyroid Autofluorescence Detection Device consists of a disposable fiber-optic probe that emits non-ionizing radiation from a near infrared (NIR) 785 nanometer (nm) laser source, and also transmits the resulting tissue NIRAF to a photo-detector. The 785 nm laser source emits a maximum power of 20 milliwatts (mW). The device has an FDA clearance for clinical use in general surgeries and dermatological use (Class 2 device).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Only participants will be masked to the intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Persistent hyperparathyroidism (Immediate)</measure>
    <time_frame>During parathyroidectomy (PTx) procedure</time_frame>
    <description>Failure of intra-operative parathyroid hormone (PTH) to normalize (defined as failure of PTH to drop &gt; 50% of its baseline value at final intra-operative PTH assay and/or failure of PTH to drop &lt; 65 pg/ml or 6.9 pmol/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistent hyperparathyroidism or hypercalcemia (transient)</measure>
    <time_frame>5-14 days after PTx procedure</time_frame>
    <description>Elevated blood calcium levels (total blood calcium level &gt; 10.5 mg/dL or 2.6 mmol/L) with/without elevated parathyroid hormone (PTH) (serum intact PTH &gt; 65 pg/ml or 6.9 pmol/L) at first postoperative visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistent hyperparathyroidism or hypercalcemia (failed parathyroidectomy)</measure>
    <time_frame>6 months after PTx procedure</time_frame>
    <description>If blood calcium with/without parathyroid hormone (PTH) has not normalized at 1st post-operative visit, calcium and/or PTH is subsequently measured as necessary. Patient is defined to have a failed parathyroidectomy if hypercalcemia/hyperparathyroidism (defined as total blood calcium level &gt; 10.5 mg/dL or 2.6 mmol/L, with/without elevated serum intact PTH &gt; 65 pg/ml or 6.9 pmol/L) persists at or after the 6th postoperative month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall number of parathyroid glands identified</measure>
    <time_frame>Immediate. During PTx procedure.</time_frame>
    <description>Overall number of parathyroid glands identified (Experimental Group: Glands identified with naked eye + NIRAF; Control Group: Glands identified with naked eye)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of parathyroid glands identified with NIRAF</measure>
    <time_frame>Immediate. During PTx procedure.</time_frame>
    <description>Number of parathyroid glands identified with NIRAF, which was not seen with surgeon's naked eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of frozen sections sent for analysis</measure>
    <time_frame>Immediate. During PTx procedure.</time_frame>
    <description>Number of frozen sections sent for analysis during the procedure to confirm potential parathyroid tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of diseased parathyroid glands identified versus preoperatively localized glands</measure>
    <time_frame>Preoperative to immediate during PTx procedure.</time_frame>
    <description>Number of diseased parathyroid glands identified intra-operatively versus glands localized preoperatively using sestamibi, CT or ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intra-operative parathyroid hormone (PTH) assays sent</measure>
    <time_frame>Immediate. During PTx procedure.</time_frame>
    <description>Number of intra-operative parathyroid hormone assays sent during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration taken to identify first parathyroid gland</measure>
    <time_frame>Immediate. During PTx procedure.</time_frame>
    <description>Duration taken to identify 1st parathyroid gland in PTx procedure - timed from skin incision to finding PG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration taken to identify last parathyroid gland</measure>
    <time_frame>Immediate. During PTx procedure.</time_frame>
    <description>Duration taken to identify last parathyroid gland in PTx procedure - timed from skin incision to finding the last PG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of parathyroidectomy (PTx) procedure</measure>
    <time_frame>Immediate. During PTx procedure.</time_frame>
    <description>Duration of PTx procedure - timed from skin incision until the surgeon notifies the anesthesia team to awaken the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration taken for intraoperative parathyroid hormone (PTH) to normalize</measure>
    <time_frame>Immediate. During PTx procedure.</time_frame>
    <description>Time taken for PTH to attain cure criteria or normalize - timed from skin incision until the PTH levels drops &gt; 50% of its baseline value and/or PTH drops &lt; 65 pg/ml or 6.9 pmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of nights spent in the hospital after parathyroidectomy</measure>
    <time_frame>0-72 hours after PTx procedure.</time_frame>
    <description>Number of nights spent for postoperative recovery in the hospital after the surgical procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of 'false positive' tissues excised by surgeon</measure>
    <time_frame>Immediate to 10 days after PTx procedure.</time_frame>
    <description>Number of tissues that were excised by surgeon assumed to be parathyroid tissue, but is later validated as non-parathyroid tissue (false positive) by histology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of doctor visits/emergency department visits or hospital admissions</measure>
    <time_frame>Up to 6 months after PTx procedure.</time_frame>
    <description>Number of doctor visits/emergency department visits or hospital admissions due to persistent hypercalcemia and/or associated symptoms after parathyroidectomy procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who have had repeat parathyroidectomy (PTx) procedure</measure>
    <time_frame>6 - 12 months after PTx procedure.</time_frame>
    <description>Number of patients with repeat PTx procedure performed after the current procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parathyroid Adenoma</condition>
  <condition>Parathyroid Neoplasms</condition>
  <condition>Parathyroid Hyperplasia</condition>
  <condition>Parathyroid Cancer</condition>
  <condition>Hypercalcemia</condition>
  <condition>Primary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>NIRAF Detection Technology +</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parathyroid gland identification will be performed with PTeye using NIRAF detection technology as an adjunctive tool in patients who undergo parathyroidectomy (PTx).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NIRAF Detection Technology -</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Parathyroid gland identification will be performed with the naked eye of the surgeon without using PTeye - NIRAF detection technology in patients who undergo parathyroidectomy (PTx).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NIRAF Detection Technology</intervention_name>
    <description>Near Infrared Autofluorescence (NIRAF) detection technology or 'PTeye' consists of a disposable fiber-optic probe that emits non-ionizing radiation from a NIR 785 nm laser source, and also transmits the resulting tissue NIRAF to a photo detector. The 785 nm laser source emits a maximum power of 20 mW. The device is FDA cleared for clinical use in general surgeries and dermatological use (Class 2 device).
After surgeon identifies a potential parathyroid gland in the surgical field, the surgeon places the fiber-optic probe of PTeye on suspect tissue and presses the device foot-pedal to activate tissue NIRAF measurement. Auditory beep at high frequency with a Detection Ratio &gt; 1.2 is interpreted by device as the suspect tissue being positive for parathyroid.</description>
    <arm_group_label>NIRAF Detection Technology +</arm_group_label>
    <other_name>PTeye Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All primary hyperparathyroidism patients eligible for parathyroidectomy (PTx). Both
             bilateral and focused mode of PTx will be considered for this study, based on the
             surgeon's preference.

          -  Re-operative primary hyperparathyroidism patients who have undergone a failed prior
             PTx.

        Exclusion Criteria:

          -  Patients with concurrent parathyroid and thyroid disease that require total
             thyroidectomy.

          -  Patients with secondary or tertiary hyperparathyroidism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen C Solorzano, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt-Ingram Service L for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Melton</last_name>
      <phone>615-936-7423</phone>
      <email>teresa.melton@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Carmen C Solorzano, MD, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colleen M Kiernan, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naira Baregamian, MD, FACS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah L Rohde, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Simental A, Ferris RL. Reoperative parathyroidectomy. Otolaryngol Clin North Am. 2008 Dec;41(6):1269-74, xii. doi: 10.1016/j.otc.2008.05.008. Review.</citation>
    <PMID>19040985</PMID>
  </reference>
  <reference>
    <citation>Cron DC, Kapeles SR, Andraska EA, Kwon ST, Kirk PS, McNeish BL, Lee CS, Hughes DT. Predictors of operative failure in parathyroidectomy for primary hyperparathyroidism. Am J Surg. 2017 Sep;214(3):509-514. doi: 10.1016/j.amjsurg.2017.01.012. Epub 2017 Jan 10.</citation>
    <PMID>28108069</PMID>
  </reference>
  <reference>
    <citation>Doherty GM, Weber B, Norton JA. Cost of unsuccessful surgery for primary hyperparathyroidism. Surgery. 1994 Dec;116(6):954-7; discussion 957-8.</citation>
    <PMID>7985102</PMID>
  </reference>
  <reference>
    <citation>Wachtel H, Cerullo I, Bartlett EK, Kelz RR, Karakousis GC, Fraker DL. What Can We Learn from Intraoperative Parathyroid Hormone Levels that Do Not Drop Appropriately? Ann Surg Oncol. 2015;22(6):1781-8. doi: 10.1245/s10434-014-4201-9. Epub 2014 Oct 30.</citation>
    <PMID>25354574</PMID>
  </reference>
  <reference>
    <citation>Mohebati A, Shaha AR. Imaging techniques in parathyroid surgery for primary hyperparathyroidism. Am J Otolaryngol. 2012 Jul-Aug;33(4):457-68. doi: 10.1016/j.amjoto.2011.10.010. Epub 2011 Dec 7. Review.</citation>
    <PMID>22154018</PMID>
  </reference>
  <reference>
    <citation>Ahuja AT, Wong KT, Ching AS, Fung MK, Lau JY, Yuen EH, King AD. Imaging for primary hyperparathyroidism--what beginners should know. Clin Radiol. 2004 Nov;59(11):967-76. Review.</citation>
    <PMID>15488844</PMID>
  </reference>
  <reference>
    <citation>Sosa JA, Powe NR, Levine MA, Udelsman R, Zeiger MA. Profile of a clinical practice: Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons. J Clin Endocrinol Metab. 1998 Aug;83(8):2658-65.</citation>
    <PMID>9709928</PMID>
  </reference>
  <reference>
    <citation>Chen H, Wang TS, Yen TW, Doffek K, Krzywda E, Schaefer S, Sippel RS, Wilson SD. Operative failures after parathyroidectomy for hyperparathyroidism: the influence of surgical volume. Ann Surg. 2010 Oct;252(4):691-5. doi: 10.1097/SLA.0b013e3181f698df.</citation>
    <PMID>20881776</PMID>
  </reference>
  <reference>
    <citation>Novis DA, Zarbo RJ. Interinstitutional comparison of frozen section turnaround time. A College of American Pathologists Q-Probes study of 32868 frozen sections in 700 hospitals. Arch Pathol Lab Med. 1997 Jun;121(6):559-67.</citation>
    <PMID>9199619</PMID>
  </reference>
  <reference>
    <citation>McWade MA, Sanders ME, Broome JT, Sol√≥rzano CC, Mahadevan-Jansen A. Establishing the clinical utility of autofluorescence spectroscopy for parathyroid detection. Surgery. 2016 Jan;159(1):193-202. doi: 10.1016/j.surg.2015.06.047. Epub 2015 Oct 9.</citation>
    <PMID>26454675</PMID>
  </reference>
  <reference>
    <citation>McWade MA, Paras C, White LM, Phay JE, Mahadevan-Jansen A, Broome JT. A novel optical approach to intraoperative detection of parathyroid glands. Surgery. 2013 Dec;154(6):1371-7; discussion 1377. doi: 10.1016/j.surg.2013.06.046.</citation>
    <PMID>24238054</PMID>
  </reference>
  <reference>
    <citation>Voelker R. Devices Help Surgeons See Parathyroid Tissue. JAMA. 2018 Dec 4;320(21):2193. doi: 10.1001/jama.2018.18768.</citation>
    <PMID>30512085</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 15, 2020</last_update_submitted>
  <last_update_submitted_qc>March 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Carmen Solorzano</investigator_full_name>
    <investigator_title>Professor of Surgery Chair, Department of Surgery Director, Vanderbilt Endocrine Surgery</investigator_title>
  </responsible_party>
  <keyword>Parathyroidectomy</keyword>
  <keyword>Intraoperative Parathyroid Identification</keyword>
  <keyword>Near Infrared Autofluorescence</keyword>
  <keyword>Persistent Hyperparathyroidism</keyword>
  <keyword>Persistent Hypercalcemia</keyword>
  <keyword>Failed Parathyroidectomy</keyword>
  <keyword>Repeat Parathyroidectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Parathyroid Neoplasms</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Informed Consent Form and Clinical Study Report will be made available to other researchers as per the specified time-frame</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Clinical Study Report will be shared 6 months after publication of trial data and will be available till end date of trial. Informed Consent Form will be shared for a year after the primary completion date of the trial.</ipd_time_frame>
    <ipd_access_criteria>Request for Individual Patient Data (IPD) - Informed consent Form and Clinical Study Report - will be reviewed by the principal investigator of this clinical trial, before granting access to IPD</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT04299425/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

